Recent pre-clinical studies suggest that the anomalies of the GH/IGF1 axis are associated with a higher prevalence of steatosis, with a more rapid progression towards non-alcoholic steatohepatitis (NASH), cirrhosis and end-stage liver disease [2]. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatohepatitis.